6:06 PM
 | 
Jan 10, 2008
 |  BC Extra  |  Company News

FDA panel to discuss telavancin, ceftobiprole

Next month, FDA's Anti-Infective Drugs Advisory Committee will review two NDAs for complicated skin and skin structure infections (cSSSIs). On...

Read the full 76 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >